1. Immune Checkpoint Inhibitors:

The immune system is essential for limiting the spread of cancer. Nonetheless, cancer cells are able to elude the immune system due to checkpoint proteins, which suppress immune cell activity.

Immune checkpoint inhibitors are medications that prevent checkpoint protein activation, liberating the immune system and enabling it to target cancer cells⁴.

Mode of Action:

The most common immune checkpoint inhibitors are antibodies that target the PD-1 or PD-L1 checkpoint proteins. The proteins PD-1 and PD-L1 are expressed on the surface of T cells, immune cells, and cancer cells, respectively⁵. When PD-1 binds to PD-L1, it sends a signal to the T cell that suppresses its activity. Immune checkpoint inhibitors block this interaction, thereby allowing T cells to become activated and attack cancer cells^5,6.

Three different groups of ICIs, including PD-1 inhibitors (Nivolumab, Pembrolizumab), PDL1 inhibitors and CTLA-4 inhibitor (Ipilimumab) have been approved by the US Food and Drug Administration (FDA) for the treatment of various types of cancer. Immune checkpoint inhibitors, or ICIs for short, are cancer immunotherapies that work by specifically targeting immunologic receptors on the surface of T cells to bolster anti-cancer immune responses (7). When ipilimumab was approved in 2011, these medicines were deemed revolutionary, signaling a major change in the way cancer is treated. In some circumstances, they provide the possibility of long-lasting effects with a lower toxicity profile. ICIs work by boosting the host immune system to fight tumor cells, in contrast to traditional therapies. Under normal circumstances, immune checkpoints are vital for preserving the equilibrium between pro- and anti-inflammatory signals. They comprise circuits that control immune cell function, both stimulatory and inhibitory. In recent times, the most often used immunotherapeutic drugs have been antibodies that target immune inhibitory receptors such CTLA-4, PD-1, and PD-L1. Clinical research is presently underway for a number of antibodies and small molecules that target different immune checkpoint proteins, such as CD39, CD73, the adenosine A2A receptor, B7H3, and CD47.

However, this treatment only benefits a small percentage of patients (20–40%), underscoring the increasing need to create predictive biomarkers. Furthermore, those suffering from advanced forms of hepatocellular carcinoma (HCC) had a low chance of responding to new therapies, underscoring the significance of biomarkers in anticipating ICI response⁷.

Clinical Efficacy: Immune checkpoint inhibitors have been shown to be effective in treating a variety of cancers, including melanoma, lung cancer, kidney cancer, and bladder cancer. In some cases, immune checkpoint inhibitors have been shown to induce durable remissions, even in patients with advanced disease^5,6.

Side Effects: Immune checkpoint inhibitors can cause a variety of side effects, including fatigue, diarrhea, rash, and pneumonitis. These side effects are usually manageable and can be treated with medication.

Thus, Checkpoint inhibitor therapy uses the body's immune system to target and destroy cancer cells, which is a paradigm shift in oncology. By disrupting inhibitory pathways, these drugs enable T cells to become fully active in their cytolytic capacity and stimulate a strong immune response against tumors. For a considerable number of patients, this immunotherapeutic strategy has shown impressive efficacy in treating a variety of malignancies, resulting in long-lasting tumor shrinkage and better clinical outcomes. Utilizing the body's natural defenses against cancer is a significant development that gives a viable path for long-term illness management and increased patient survival^5-7.

2. CAR-T cell therapy:

CAR-T cell (Chimeric antigen receptor T-cell) therapy is a new rapidly developing immunotherapy showing promise in treating B-cell tumors.

Our primary components are one or more intracellular signaling domains, a hinge region, a transmembrane domain, and an extracellular target antigen-binding domain⁸. Building on research into how immune cells function, CAR-T therapies are showing success and attracting significant investment as clinical trials progress globally⁹. CAR-T cell therapy shows promise in treating some blood cancers, but challenges remain. These challenges include severe side effects, limited effectiveness against some cancers, and difficulty reaching all tumor cells. Researchers are developing new methods to engineer CAR-T cells to be more effective and safer for broader cancer treatment⁸. CAR-T cell therapy holds promise for cancer treatment, but faces

Limitations:

Cancer cells can escape targeting Treated with strategies like targeting multiple antigens on cancer cells. Cancer cells are able to avoid being targeted, even in the face of therapeutic approaches such concentrating on several antigens on cancer cells. On the other hand, the process might harm healthy cells. Targeting specific alterations specific to cancer cells is being investigated, in addition to approaches to get around issues such as CAR-T cells not being able to reach tumors; these include targeted delivery and modifying CAR-T cells to go over barriers. Another problem is tumor-induced immune suppression, which has led to research on how to improve the capacity of CAR-T cells to fight suppression or how to combine CAR-T with checkpoint blockade. Additionally, studies are being conducted to reduce the toxicity of CAR-T cells and their structure in an attempt to lessen the negative consequences that these cells can have¹⁰.

Mode of Action:

Utilizing the immune system to specifically eradicate cancerous cells is a novel strategy made possible by chimeric antigen receptor (CAR) T-cell therapy. T cells from a patient are manipulated ex vivo during this procedure. In a strictly regulated lab setting, T cells are taken out of circulation and genetically altered. Through genetic alteration, a novel chimeric construct encoding a CAR molecule is introduced. Customized antibody receptors, or CARs, are engineered to precisely identify particular expression of TAA (Tumor-associated antigens) on the surface of cancer cells. These receptors are synthetically produced by fusing the intracellular signaling domains of T cell receptors with the antigen-binding domain of a monoclonal antibody. They do not exist naturally in the human immune system. After integration of CAR, the T cells go through an ex vivo expansion phase during which they are stimulated to multiply into a powerful cellular army consisting of millions of cells. After that, the patient's blood is once again infused with the amplified and reprogrammed CAR T cells. Ideally, these modified T cells will use their CARs to identify and attach to the target TAAs on cancer cells, launching powerful cytolytic effector actions that ultimately lead to the precise destruction of cancerous cells.

Figure 2: CAR-T cell therapy

3. Monoclonal antibodies:

In 1890, Behring and Shibasaburo first described antibodies as a neutralizing agent found in blood through their research on animal models of diphtheria. A number of important scientific discoveries over the course of the next century would make the use of antibodies as a cancer treatment possible^11,12. In 1947, Astrid Fagraeus demonstrated that the adaptive immune system's plasma B cells produced antibodies. Heidelberger and Avery had discovered that antibodies were proteins with specific antigen detection capabilities. Sir Gustav Nossal then provided evidence that a single B cell clone produces a single type of antibody, so bolstering the theory of clonal selection. Therefore, antibodies made from clones of a single B cell that are all specific to different areas of an antigen are known as monoclonal antibodies^11-13. It was first described as a neutralizing agent in blood in 1890 by Behring and Shibasaburo in their work on animal models of diphtheria. Over the course of the next century, a series of important scientific discoveries would make the use of antibodies as a cancer treatment possible.

Over time, there has been a significant shift in our knowledge of antibodies. Scientists discovered them as disease-fighting fighters in our bodies in the late 19th century. The picture was more apparent by the middle of the 20th century. B cells produced antibodies, which were incredibly precise little assassins. They could go after so-called epitopes, which are particular surface weaknesses on intruders. These resembled a horde of clones, all exactly engineered to hunt down a particular epitope. But there were initial obstacles. Early mouse-derived versions made people's immune systems react inappropriately. Fortunately, progress has removed this barrier with the development of fully human and humanized. This opened the door for a revolution in cancer treatment, as monoclonal antibodies are now potent tools against a wide range of illnesses.

Mode of Action:

Different signals are necessary for cancer cells to grow and survive. Chimeric monoclonal antibodies (cmAbs) are an effective instrument that can interfere with these signals and use a variety of techniques to eradicate cancer cells. Blocking communications that often encourage cancer cell survival is one way that cmAbs function. They can also cause the cancer cells to undergo apoptosis, or programmed cell death. Targeted delivery vehicles can also be employed with CmAbs. When cytotoxic medications or radioactive elements are attached to cmAbs, they are directly delivered to cancer cells, increasing their effectiveness and reducing damage to healthy tissue. Moreover, CmAbs can combat cancer cells by utilizing the body's natural immune system. The destruction of cancer cells by immune cells that identify and bind to cmAbs is known as antibody-dependent cellular cytotoxicity, or ADCC. CMSBs have the ability to directly harm cancer cells by activating complement proteins, which are another component of the immune system. By engulfing and eliminating foreign items through the process of phagocytosis, immune cells can destroy cancer cells with cmAbs. To combat cancer cells directly, certain cmAbs can stimulate T lymphocytes. In essence, they shut off the tumor's supply of oxygen and nutrients, impeding its growth and dissemination. They do this by targeting molecules involved in blood vessel formation. The several mechanisms that cmAbs utilize provide a multimodal strategy to the fight against cancer¹³.

By employing these mechanisms, CmAbs can cause tumor regression by directly killing cancer cells, stimulating the immune system to attack them, and depriving them of essential resources¹⁴.

4. Cancer Vaccines:

Vaccines are currently positioned for success for several reasons, even though five decades of study have produced numerous failures. T cells can now definitely treat cancer patients, as demonstrated by CAR T cells and bispecific T cell engagers. Furthermore, checkpoint inhibition has demonstrated that proper antigen presentation is necessary for endogenous T cell priming, and that patients' own T cells must be primed against their own TAAs in order for tumor regression to occur. These findings contrast with earlier decades' findings. What are the most promising kinds of TAAs? It is attractive to target mutant TSAs (either with predetermined tailored or anonymous vaccinations), but assessing the ensuing immune responses is crucial for advancing the treatment into the clinic^15,16.

Prior to evaluating anti-cancer efficacy, measuring pharmacodynamic effects is the gold standard for developing cancer therapies. Small-molecule chemotherapeutics would face several setbacks if inefficient kinase inhibitors were included into efficacy studies. Immunotherapies should have comparable metrics to pathogen vaccines, as those against coronavirus illness 2019, which need strong humoral responses prior to clinical effectiveness studies. Due to the absence of consistently detectable "immunodynamics" or pharmacodynamics of cancer vaccines, inadequately supported techniques have progressed to late-phase clinical trials, where they have been repeatedly pushed back by failures. It will be essential to conduct efficient immune surveillance to ascertain if cancer vaccines achieve the desired immunologic effects134 and to advance only immunologically successful candidates to bigger trials and suitable patient subsets^15-17.

Mode of Action:

Therapeutic cancer vaccines work by enhancing the immune system of the patient in order to aid in the specific destruction of cancerous cells. Tumor-associated antigens (TAAs) are molecules that are only expressed on the surface or in the cytoplasm of cancer cells. These vaccines take use of this property. Through the integration of TAAs or their subunits into a vaccine formulation, researchers can utilize the immune system's innate antigen presentation mechanism. Antigen-presenting cells (APCs) recognize the vaccine-delivered TAAs and engage in internalization, processing, and presentation of these antigen pieces on their surface in association with major histocompatibility complex (MHC) molecules. Cytotoxic T lymphocytes (CTLs), which identify the MHC-TAA complex and become primed to launch a focused attack against cancer cells expressing the relevant antigen, are activated by this presentation of antigen. Cancer vaccines are essentially immunological training programmers that help the immune system recognize the differences between healthy cells and cancerous cells by identifying particular surface markers. This process ultimately results in the elimination of cancerous cells¹⁶.

Figure 3: MOA of cancer vaccines

5. Adoptive cell transfer:

Adoptive Cell Transfer (ACT): Represents a state-of-the-art method of tumor treatment. It entails giving patients both nonspecific and specific activated immune cells in order to boost the body's immune response and either directly or indirectly target and destroy tumor cells.

The goal: The primary objective of ACT is to establish a potent and targeted cellular response against malignant cells. The reinfused effector T cells are designed to recognize and eliminate tumor cells with heightened efficacy compared to the endogenous immune response.

ACT has demonstrated significant promise in treating various malignancies, particularly hematological malignancies and advanced solid tumors like melanoma. Clinical trials are ongoing to evaluate its efficacy in a broader spectrum of cancers^18,19.

Key Steps:

1. Apheresis: Patient-derived T cells are extracted from the peripheral blood through apheresis, a blood cell separation technique.

2. Vitro in Expansion: The harvested T cells undergo activation and expansion in a controlled laboratory environment using specific cytokines and stimuli.

3. Genetic Modification (Optional): In some instances, the T cells may be engineered using viral vectors to express chimeric antigen receptors (CARs) or other immunomodulatory molecules, enhancing their tumor recognition and cytolytic potential.

4. Reinfusion: The expanded and/or genetically modified T cell population is then reintroduced into the patient via intravenous infusion.

Types of ACT Therapy:

1. Tumor-infiltrating Lymphocyte (TIL) Therapy: This approach utilizes T cells naturally present within the tumor microenvironment, which are harvested, expanded, and reinfused.

2. CAR T-cell Therapy: Genetically engineered T cells expressing CARs, which confer recognition of specific tumor-associated antigens, are employed for targeted immunotherapy. ACT is a rapidly evolving field with ongoing research focused on optimizing cell expansion protocols, improving targeting strategies, and overcoming challenges associated with graftversus-host disease (GVHD) in allogeneic settings²⁰.

6. Tumor-infiltrating lymphocytes (TIL) therapy:

CAR-T cell therapy, a promising treatment where a patient's own T cells are engineered to target cancer cells, it has been successful for certain blood cancers. However, it hasn't shown the same effectiveness against solid tumors. This highlights the need for further research into TIL therapy, a precursor to CAR-T, to improve treatment options for solid tumor patient²¹. CAR-T cell therapy, a promising treatment where a patient's own T cells are engineered to target cancer cells, has been successful for certain blood cancers. However, it hasn't shown the same effectiveness against solid tumors. This highlights the need for further research into TIL therapy, a precursor to CAR-T, to improve treatment options for solid tumor patient²².

New approaches to cancer treatment have been made possible by immunotherapy, particularly cell-based immunotherapy. Adopting cell transfer of tumor-infiltrating lymphocytes (TILs) for solid tumors with advanced stages has proven to be effective, according to recent clinical research²³.

The TIL-ACT process begins with the extraction of naturally infiltrating lymphocytes from tumor tissues, which are then expanded in vitro. These cells are then given to patients to specifically target and eradicate tumor cells after being enhanced with a high dosage of IL-2. Patients go through a non-myeloablative (NMA) lymphodepletion therapy before receiving TIL products. In the realm of TIL-ACT, the research group led by Dr. Steven Rosenberg has made significant contributions^20,21,23.

Mode of action: TIL treatment effectively targets and eradicates cancer cells by utilizing the patient's own immune system, specifically T lymphocytes. TILs may more successfully address tumor heterogeneity because of their varied TCR clones, which provide a wider range of tumor antigen recognition. TILs are isolated from new tumor tissues, given cytokines like IL-2 to promote their multiplication in vitro, and then the patient is given access to them again. The amplification process increases TIL production and function, which in turn triggers apoptosis in tumor cells.

Significantly, TIL therapy has proven to be extremely effective in preclinical research, especially when paired with IL-2, as seen by full cure rates in mouse models with metastatic tumors. Furthermore, complex interactions with immunological checkpoints such as PD-1 and 4-1BB are involved in the regulation of TIL activity within tumors. Therapeutic effects can be improved by altering these checkpoints, which can increase TIL proliferation and function. Costimulatory and co-inhibitory molecules like CTLA4 are involved, which emphasizes how intricate immune regulation is and how crucial it is to target these pathways for successful immunotherapy^20,21.

Recent advances in immunotherapy against cancer:

It is not a new idea to engage the immune system to combat cancer; Coley reported in 1891 that erysipelas injections were used to cure three cases of sarcoma. But less than a decade has gone by since oncologists, physicians, and cancer researchers started paying close attention to cancer immunotherapy. Research in this field—basic, translational, and clinical—has increased due to the remarkable evolution and development of cancer immunotherapy.

Cancer immunotherapy holds immense promise for battling various malignancies. To maximize its effectiveness, researchers are focusing on four key areas:

1. Deciphering the Battlefield: Understanding the tumor microenvironment, a complex ecosystem of immune cells and cancer cells, is crucial. Researchers are analyzing the immune landscape within tumors to identify the types and activation state of immune cells present. This information helps predict how a patient's immune system might react to immunotherapy.

2. Predicting Response: Identifying biomarkers - measurable indicators in blood, tissue, or genes - is critical. By analyzing these biomarkers, scientists hope to predict how a patient will respond to specific immunotherapies. This allows for personalized treatment plans, maximizing benefits and minimizing unnecessary side effects.

3. Understanding Resistance: Unfortunately, some cancers develop resistance to immunotherapy. Researchers are investigating the mechanisms behind this resistance, both inherent and acquired by the tumor. This knowledge will guide the creation of tactics to combat resistance and enhance the treatment response's resilience.

4. Next-Generation Therapies: Innovation is driving the development of novel immunotherapies. This includes more precise checkpoint inhibitors, next-generation CAR Tcell therapies with enhanced targeting and persistence, personalized cancer vaccines targeting a patient's specific mutations, and improved oncolytic viruses for increased tumor killing and immune stimulation.

These advancements, often transferable across different cancers due to the broad applicability of immunotherapy, hold the potential to significantly improve treatment outcomes for a wider range of cancer patients.

Tumor development can be inhibited and eliminated using immunotherapy, something that has not been possible with conventional chemotherapy. Because of immunotherapy's scope and specificity, greater outcomes can be achieved more quickly and with fewer adverse effects overall. It is abundantly evident that using antibodies particularly monoclonal antibodies is a very promising strategy in the battle against cancer. With a brief half-life within the body, monoclonal antibodies exhibit extreme specificity towards their intended targets. In addition to enhancing the therapy's anti-cancer properties, this reduces undesirable side effects.

With a brief half-life within the body, monoclonal antibodies exhibit extreme specificity towards their intended targets. This reduces unwanted side effects while enhancing the therapy's anti-cancer effectiveness. This suggests that monoclonal antibody immunotherapy is far safer than other anti-cancer medicines, such small chemicals, but regrettably, the treatment's short half-life limits its effectiveness.

One potential solution to this issue might be the combination of two simultaneous treatments, such as chemotherapy and monoclonal antibodies. We are hoping that the focus will change from the more harmful impacts of the latter, which also damage healthy cells, to the more benign outcomes of the former.

Through the development of immunotherapies for specific populations, immunotherapy combos, or immunotherapies in neo adjuvant or adjuvant contexts, the roles and effects of cancer immunotherapies will significantly increase. The investigation of novel prediction biomarkers for immunotherapies, the creation of tactics to address innate.

Immunotherapy is transforming cancer treatment, offering patients with some cancers the potential for long-term remission or even a cure. Here's a dive into some exciting recent advances, along with credible sources for further exploration^24-30.

Challenges in the field of immunotherapy:

Current cancer immunotherapies face the challenge of developing broadly efficacious agents. While dramatic responses in certain patients demonstrate the potential for immune mediated tumor control, the majority of patients and cancer types show limited benefit. This variability is likely due to a combination of factors Limited Biomarker Identification, We need to identify additional markers that predict response to immunotherapy.

Cancer immunotherapy faces several challenges due to the complex nature of cancer and the immune system. Here's a breakdown of these hurdles

Tumor Heterogeneity:

Tumors are not uniform. They can harbor a variety of cancer cells with different mutations and characteristics. This diversity makes it difficult to develop a single therapy that targets all cancer cells within a patient.

Cancer Specificity:

A number of factors, such as the kind and extent of carcinoma, may vary the effectiveness of immunotherapy. Some cancers are simply less susceptible to immune attack than others. Understanding the specific biology of each cancer is crucial for tailoring immunotherapy approaches.

Prior Treatments:

The immune system may become weakened or altered as a result of prior therapies like radiation or chemotherapy, which may make it more difficult for the body to react to immunotherapy. When creating an immunotherapy plan for a patient, physicians must take their treatment history into account.

Immunosuppressive Tumor Biology:

Some cancers are adept at suppressing the immune system, creating a shield against immunotherapy. These tumors actively dampen immune response, making it harder for the body's defenses to recognize and eliminate cancer cells.

The moderate effectiveness of medicines targeting specific mutations in cancer immunotherapy has subdued the original euphoria surrounding them. This limited effectiveness highlights the urgent need for more all-encompassing strategies. Cancer is a crafty enemy, and there are many intricate factors that interact to affect a tumor's reaction to immunotherapy. One of the main challenges is tumor heterogeneity, which occurs when a single tumor has several populations of cancer cells with different mutations. Treatments aimed at a single mutation may eradicate a particular subgroup, but resistant clones may develop and accelerate the growth of the tumor. Additionally, the ecosystem that surrounds the tumor, known as the tumor microenvironment, is crucial. The ability of immune cells to invade and fight a tumor can be impeded by immunesuppressive cells and restricted blood supply. Lastly, the immune system of the patient itself is involved.

The application of medication combinations that target many mutations and disease pathways may reinforce this "reductionist" approach. Twenty percent of hematological cancer mortality is caused by multiple myeloma (MM), the second most frequent hematological cancer. In bone marrow (BM), it is a malignant illness of the monoclonal antibody producing plasma cells. The bone marrow microenvironment plays a critical role in MM cell survival and treatment resistance. Antibody therapies comprise a range of strategies, such as antibody-drug conjugates (ADCs), that are intended to directly cause MM cells to undergo programmed cell death, or apoptosis.

Improving the ability of important immune system weapons to bind could help battle Multiple Myeloma (MM). Although therapies such as death receptor antibodies, bispecific antibodies, and CAR T-cell therapy show promise, scientists are currently investigating strategies to enhance their ability to identify and eradicate myeloid cells. Creating multispecific CAR Tcells is one strategy. These T cells have undergone modification to express two or more CARs, each of which targets a distinct antigen unique to MM cells. The total avidity, or binding strength, of the T cells towards the MM cells may be markedly enhanced by this tactic. This multifaceted method can defeat potential escape strategies used by MM cells by focusing on several weaknesses in the cancer cells, which will result in a more potent treatment effect^24-30.

SUMMARY:

To sum up, immunotherapy is a huge advance in the fight against cancer, with encouraging results and the chance to raise patient quality of life and survival rates. Tumor-infiltrating lymphocytes, immune checkpoint inhibitors, CAR-T cell therapy, monoclonal antibodies, cancer vaccines, and adoptive cell transfer are just a few of the techniques that have demonstrated promise in the management of many types of cancer. But they are not without difficulties and drawbacks. Tumor heterogeneity—the possibility of many populations of cancer cells with distinct mutations within a single tumor—is one of the major obstacles' immunotherapy faces. The development of effective medicines that target all cancer cells is hampered by this intricacy. Treatment outcomes are also significantly influenced by the tumor microenvironment and the immune system's reaction. Despite these difficulties, continued development and research endeavors are concentrated on resolving these barriers to improve immunotherapy's effectiveness and safety. Techniques include combining several therapies to target various mutations and pathways, enhancing immune cells' capacity to discover and destroy cancer cells, and finding biomarkers to forecast therapy response are some of the approaches being investigated.

REFERENCES:

1. Ling SP, Ming LC, Dhaliwal JS, Gupta M, Ardianto C, Goh KW, et al. Role of Immunotherapy in the Treatment of Cancer: A Systematic Review. Vol. 14, Cancers. MDPI; 2022.

2. Neves H, Kwok HF. Recent advances in the field of anti-cancer immunotherapy. Vol. BBA Clinical. Elsevier; 2015. p. 280–8.

3. Wang RF. A special issue on cancer immunotherapy. Vol. 27, Cell Research. Nature Publishing Group; 2017. p. 1–2.

4. Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, et al. Immune Checkpoint Inhibitors in Cancer Therapy. Vol. 29, Current Oncology. MDPI; 2022. p. 3044–60.

5. Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Vol. 21, Nature Reviews Cancer. Nature Research; 2021. p. 298–312.

6. Hamaï A, Benlalam H, Meslin F, Hasmim M, Carré T, Akalay I, et al. Immune surveillance of human cancer: If the cytotoxic T-lymphocytes play the music, does the tumoral system call the tune? Vol. 75, Tissue Antigens. 2010. p. 1–8.

7. Alturki NA. Review of the Immune Checkpoint Inhibitors in the Context of Cancer Treatment. Vol. 12, Journal of Clinical Medicine. Multidisciplinary Digital Publishing Institute (MDPI); 2023.

8. Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Vol. 11, Blood Cancer Journal. Springer Nature; 2021.

9. Zhang Q, Ping J, Huang Z, Zhang X, Zhou J, Wang G, et al. CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead. Vol. 2020, Journal of Immunology Research. Hindawi Limited; 2020.

10. Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, et al. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. J Immunother Cancer. 2017 Mar 21;5(1).

11. Mclaughlin P, Grillo-L6pez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program. Vol. 16, J Clin Oncol. 1998.

12. Benavente S, Huang S, Armstrong EA, Chi A, Hsu KT, Wheeler DL, et al. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. Clinical Cancer Research. 2009 Mar 1;15(5):1585–92.

13. Zahavi D, Weiner L. Monoclonal antibodies in cancer therapy. Vol. 9, Antibodies. MDPI; 2020. p. 1–20.

14. Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. Vol. 62, International Immunopharmacology. Elsevier B.V.; 2018. p. 29–39.

15. Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, et al. Phase i safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clinical Cancer Research. 2008 May 15;14(10):3044–51.

16. Lin MJ, Svensson-Arvelund J, Lubitz GS, Marabelle A, Melero I, Brown BD, et al. Cancer vaccines: the next immunotherapy frontier. Vol. 3, Nature Cancer. Nature Research; 2022. p. 911–26.

17. Titov A, Zmievskaya E, Ganeeva I, Valiullina A, Petukhov A, Rakhmatullina A, et al. Adoptive immunotherapy beyond CAR T-cells. Vol. 13, Cancers. MDPI AG; 2021. p. 1–23.

18. Sharkey RM, Goldenberg DM. Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates. CA Cancer J Clin. 2006 Jul 1;56(4):226–43.

19. Zhao D, Zhu D, Cai F, Jiang M, Liu X, Li T, et al. Current Situation and Prospect of Adoptive Cellular Immunotherapy for Malignancies. Vol. 22, Technology in Cancer Research and Treatment. SAGE Publications Inc.; 2023.

20. Zhao Y, Deng J, Rao S, Guo S, Shen J, Du F, et al. Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges. Vol. 14, Cancers. MDPI; 2022.

21. Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Vol. 94, American Journal of Hematology. Wiley-Liss Inc.; 2019. p. S3–9.

22. Emens LA, Ascierto PA, Darcy PK, Demaria S, Eggermont AMM, Redmond WL, et al. Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. Vol. 81, European Journal of Cancer. Elsevier Ltd; 2017. p. 116–29.

23. Debela DT, Muzazu SGY, Heraro KD, Ndalama MT, Mesele BW, Haile DC, et al. new approaches and procedures for cancer treatment: Current perspectives. Vol. 9, SAGE Open Medicine. SAGE Publications Ltd; 2021.

24. Dhar R, Seethy A, Singh S, Pethusamy K, Srivastava T, Talukdar J, et al. Cancer immunotherapy: Recent advances and challenges. Vol. 17, Journal of Cancer Research and Therapeutics. Wolters Kluwer Medknow Publications; 2021. p. 834–44.

25. Baronzio Gianfranco G, Parmar Gurdev, Ballerini Marco, Kiselevsky Mikhail, Cassuti Valter, Irina Zh Shubina, et al. Update on the challenges and recent advances in cancer immunotherapy. Immunotargets Ther. 2013 Jun;39.

26. Yang L, Ning Q, Tang SS. Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment. Vol. 2022, Journal of Immunology Research. Hindawi Limited; 2022.

27. Baronzio Gianfranco G, Parmar Gurdev, Ballerini Marco, Kiselevsky Mikhail, Cassuti Valter, Irina Zh Shubina, et al. Update on the challenges and recent advances in cancer immunotherapy. Immunotargets Ther. 2013 Jun;39.

28. Esfahani K, Roudaia L, Buhlaiga N, Del Rincon S V., Papneja N, Miller WH. A review of cancer immunotherapy: From the past, to the present, to the future. Current Oncology. 2020;27(S2):87–97.

29. Suda K. Recent advances in cancer immunotherapy. Biomolecules. 2021 Feb 1;11(2):1–3.

30. Holthof LC, Mutis T. Challenges for immunotherapy in multiple myeloma: Bone marrow microenvironment-mediated immune suppression and immune resistance. Vol. 12, Cancers. MDPI AG; 2020.

Received on 22.04.2024 Revised on 11.10.2024

Accepted on 01.01.2025 Published on 27.02.2025

Available online from March 05, 2025

Asian J. Pharm. Tech. 2025; 15(1):57-65.

DOI: 10.52711/2231-5713.2025.00010

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.